CRY

Artivion, Inc. [CRY] Stock Forecast

Q: What is Artivion, Inc. stock symbol ?

Artivion, Inc. is a US stock, located in Kennesaw of Georgia and trading under the symbol CRY

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CRY Stock Summary

Earnings have grown 12.82% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

CRY has less than 1 year of cash runway

Debt-to-Equity ratio of 1.11 is considered moderate, deeper research suggested.

In the News

CRY Financial details

Company Rating

Buy

Market Cap

725.15M

Income

-30.69M

Revenue

354M

Book val./share

6.89

Cash/share

1.44

Dividend

Dividend %

Employees

1.2K

Optionable

Shortable

Yes

Earnings

09 Feb 2022

P/E

-45.43

Forward P/E

PEG

-8.07

P/S

92571546.25

P/B

2.24

P/C

12.42

P/FCF

-46.61

Quick Ratio

2.52

Current Ratio

5.51

Debt / Equity

1.11

LT Debt / Equity

1.08

EPS (TTM)

-0.75

EPS next Y

EPS next Q

EPS this Y

56.25%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

5.09%

Revenue Q/Q

6.62%

EPS Q/Q

-59.5%

SMA20

SMA50

SMA100

Inst Own

91.2%

Inst Trans

ROA

-2%

ROE

-5%

ROC

-0.01%

Gross Margin

66%

Oper. Margin

-3%

Profit Margin

-5%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

17.49-18.22

52W High

-0.67%

52W Low

+5.18%

RSI

Rel Volume

1.29

Avg Volume

200.07K

Volume

257.46K

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.53016

Volatility

0%, 0%

Prev Close

Price

17.88

Change

1.36%

CRY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	7.44	6.69	7.67	7.84	8.69
Net income per share	0.05	-0.44	-0.38	-0.48	-0.75
Operating cash flow per share	0.43	0.33	-0.07	-0.13	0.46
Free cash flow per share	0.21	0.13	-0.4	-0.4	0.27
Cash per share	0.94	1.65	1.41	0.98	1.45
Book value per share	7.7	8.68	7.71	7.1	6.92
Tangible book value per share	-1.58	-4.18	-3.87	-3.55	-3.38
Share holders equity per share	7.7	8.68	7.71	7.1	6.92
Interest debt per share	7.01	8.82	9.72	9.37	8.28
Market cap	1.01B	893.9M	793.3M	485.19M	728.48M
Enterprise value	1.22B	1.15B	1.1B	802.67M	1.03B
P/E ratio	584.61	-53.58	-53.48	-25.28	-23.83
Price to sales ratio	3.64	3.53	2.65	1.55	2.06
POCF ratio	63.53	72.27	-306.89	-94.16	39.22
PFCF ratio	129.66	177.33	-50.61	-30.58	65.36
P/B Ratio	3.52	2.72	2.64	1.71	2.59
PTB ratio	3.52	2.72	2.64	1.71	2.59
EV to sales	4.4	4.54	3.68	2.56	2.91
Enterprise value over EBITDA	73.59	-2.41K	108.79	31.25	27.17
EV to operating cash flow	76.86	92.92	-425.66	-155.77	55.39
EV to free cash flow	156.85	227.99	-70.19	-50.58	92.31
Earnings yield	0	-0.02	-0.02	-0.04	-0.04
Free cash flow yield	0.01	0.01	-0.02	-0.03	0.02
Debt to equity	0.86	0.97	1.2	1.25	1.11
Debt to assets	0.4	0.4	0.46	0.47	0.39
Net debt to EBITDA	12.76	-536.59	30.36	12.36	7.93
Current ratio	4.15	3.88	5.51	4.98	3.99
Interest coverage	-0.12	0.15	-0.82	0.18	0.58
Income quality	9.2	-0.74	0.17	0.27	-0.61
Dividend Yield	0	0	0	0	0
Payout ratio	2.77	-0.15	-0.25	0	0
Sales general and administrative to revenue	0.52	0.55	0.56	0.5	0
Research and developement to revenue	0.08	0.1	0.12	0.12	0.08
Intangibles to total assets	0.57	0.62	0.57	0.56	0.53
Capex to operating cash flow	-0.51	-0.59	5.06	2.08	-0.4
Capex to revenue	-0.03	-0.03	-0.04	-0.03	-0.02
Capex to depreciation	-0.44	-0.35	-0.55	-0.48	-0.32
Stock based compensation to revenue	0.03	0.03	0.04	0.04	0.04
Graham number	2.83	9.28	8.13	8.75	10.8
ROIC	0	0	-0.02	0.01	0.03
Return on tangible assets	0.01	-0.06	-0.04	-0.06	-0.08
Graham Net	-5.84	-8.59	-9.11	-8.74	-8.72
Working capital	142.2M	174.12M	202.74M	197.66M	173M
Tangible asset value	-58.74M	-158.41M	-150.77M	-141.95M	-137.79M
Net current asset value	-132.57M	-226.1M	-244.63M	-231.14M	-279.75M
Invested capital	0.86	0.97	1.2	1.25	1.11
Average receivables	53.65M	52.31M	53.43M	63.84M	71.86M
Average payables	8.67M	9.71M	10.01M	11.2M	12.66M
Average inventory	49.27M	63.05M	75M	75.72M	78.23M
Days sales outstanding	73.81	70.27	70.97	80.94	76.44
Days payables outstanding	38.36	41.11	37.45	39.38	34.72
Days of inventory on hand	207.82	312.01	277.28	244.32	213.68
Receivables turnover	4.94	5.19	5.14	4.51	4.77
Payables turnover	9.52	8.88	9.75	9.27	10.51
Inventory turnover	1.76	1.17	1.32	1.49	1.71
ROE	0.01	-0.05	-0.05	-0.07	-0.11
Capex per share	-0.22	-0.19	-0.34	-0.27	-0.18

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.98	2.06	2.19	2.15	2.29
Net income per share	0.05	-0.33	-0.08	-0.24	-0.1
Operating cash flow per share	-0.01	-0.15	0.17	0.18	0.26
Free cash flow per share	-0.07	-0.22	0.14	0.14	0.21
Cash per share	0.98	0.76	1.2	1.31	1.44
Book value per share	7.09	6.92	6.93	6.65	6.89
Tangible book value per share	-3.54	-3.62	-3.44	-3.5	-3.37
Share holders equity per share	7.09	6.92	6.93	6.65	6.89
Interest debt per share	9.03	8.95	8.87	8.91	7.78
Market cap	486.34M	529.66M	700.58M	619.76M	731.26M
Enterprise value	803.82M	854.54M	1.01B	923.78M	1.03B
P/E ratio	56.06	-9.79	-51.79	-15.81	-45.99
Price to sales ratio	6.13	6.36	7.85	7.05	7.81
POCF ratio	-2.24K	-86.07	101.4	85.7	69.06
PFCF ratio	-168.58	-58.87	122.41	107.63	84.42
P/B Ratio	1.71	1.89	2.48	2.28	2.6
PTB ratio	1.71	1.89	2.48	2.28	2.6
EV to sales	10.12	10.27	11.28	10.51	11.01
Enterprise value over EBITDA	92.96	293.56	-210.48	313.89	325.24
EV to operating cash flow	-3.7K	-138.86	145.74	127.73	97.43
EV to free cash flow	-278.62	-94.98	175.95	160.43	119.1
Earnings yield	0	-0.03	0	-0.02	-0.01
Free cash flow yield	-0.01	-0.02	0.01	0.01	0.01
Debt to equity	1.25	1.27	1.26	1.31	1.11
Debt to assets	0.47	0.47	0.46	0.46	0.39
Net debt to EBITDA	36.72	111.6	-64.04	103.3	94.7
Current ratio	4.98	5.47	4.69	4.86	3.99
Interest coverage	0.6	-0.46	1.21	-0.19	0.51
Income quality	-0.1	0.45	-2.04	-0.74	-2.67
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.46	0.55	0.64	0.58	0
Research and developement to revenue	0.1	0.09	0.08	0.07	0.08
Intangibles to total assets	0.56	0.56	0.54	0.54	0.53
Capex to operating cash flow	12.29	0.46	-0.17	-0.2	-0.18
Capex to revenue	-0.03	-0.03	-0.01	-0.02	-0.02
Capex to depreciation	-0.49	-0.5	-0.21	-0.26	-0.33
Stock based compensation to revenue	0.04	0.04	0.04	0.04	0.04
Graham number	2.94	7.22	3.6	5.99	3.88
ROIC	0	-0.01	0.01	0	0.03
Return on tangible assets	0.01	-0.04	-0.01	-0.03	-0.01
Graham Net	-8.71	-8.86	-8.72	-8.78	-8.68
Working capital	197.66M	196.72M	207.67M	212.15M	173M
Tangible asset value	-141.95M	-146.37M	-140.05M	-143.03M	-137.79M
Net current asset value	-231.14M	-236.48M	-231.46M	-235.7M	-279.75M
Invested capital	1.25	1.27	1.26	1.31	1.11
Average receivables	67.31M	68.15M	67.98M	68.76M	71.2M
Average payables	11.36M	10.74M	9.96M	10.64M	12.07M
Average inventory	73.76M	75.38M	77.37M	78.63M	80.38M
Days sales outstanding	78.88	72.14	69.84	69.94	71.23
Days payables outstanding	37.89	28.9	30.19	30.83	36.8
Days of inventory on hand	235.11	232.68	226.56	224.52	226.49
Receivables turnover	1.14	1.25	1.29	1.29	1.26
Payables turnover	2.38	3.11	2.98	2.92	2.45
Inventory turnover	0.38	0.39	0.4	0.4	0.4
ROE	0.01	-0.05	-0.01	-0.04	-0.01
Capex per share	-0.07	-0.07	-0.03	-0.04	-0.05

CRY Frequently Asked Questions

What is Artivion, Inc. stock symbol ?

Artivion, Inc. is a US stock , located in Kennesaw of Georgia and trading under the symbol CRY

What is Artivion, Inc. stock quote today ?

Artivion, Inc. stock price is $17.88 today.

Is Artivion, Inc. stock public?

Yes, Artivion, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 200.07K
Market Capitalization 725.15M
Employee 1.2K
CEO Mr. James Mackin
Headquarters Kennesaw,GEORGIA,US
IPO Date 1993-02-12
Website https://artivion.com

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.